 |
Shanghai, China; Cambridge, Massachusetts, USA; and Rotterdam, NetherlandsJune 12, 2026 /PRNewswire/ — Harbour BioMed (stock code: 02142.HK), a global biopharmaceutical company focused on the discovery and development of innovative antibody therapies in immunology, oncology, and other therapeutic areas, today announced the appointment of Dr. Dhavalkumar Patel as a scientific advisor.
Dr. Patel brings over 20 years of drug innovation experience from both academia and industry, and currently serves as Executive Vice President and Chief Scientific Officer at Sana Biotechnology.
Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice President and Chief Scientific Officer at UCB, where he and his team advanced the regulatory approvals of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®), and zilucoplan (Zilbrysq®). Before UCB, he spent 10 years at Novartis, serving as Head of the Novartis Institutes for BioMedical Research (NIBR) Europe, leading research in autoimmune, transplant, and inflammatory diseases, and contributing to the regulatory approvals of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) across multiple indications. He also served as an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel was a board member of Inflazome, which was acquired by Roche in 2020. He currently serves on the boards of Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and is Chairman of the Board at Mimetas BV.
Before entering industry in 2006, Dr. Patel was a Distinguished Professor of Medicine, Chief of the Division of Rheumatology, Allergy, and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill. He also spent nine years at Duke University Medical Center, where he served as Chief of the Division of Allergy and Immunology. Dr. Patel earned his bachelor’s, doctoral, and medical degrees in Microbiology and Immunology from Duke University, and holds board certifications in Internal Medicine, Rheumatology, Allergy, and Immunology.
Dr. Wang Jinsong, Founder, Chairman, and CEO of Harbour BioMed, said: “We are delighted to welcome Dr. Patel to our Scientific Advisory Board. His deep expertise in immunology, outstanding track record in drug development, and strategic insights at the board level will be invaluable to the company. We look forward to his guidance as we continue to build an industry-leading immunology pipeline.”
Dr. Dhavalkumar Patel said: “I am honored to join Harbour BioMed as a scientific advisor. Harbour BioMed has built an impressive portfolio of innovative antibody candidates targeting key immune pathways. I believe the company is well-positioned to make meaningful progress in areas of high unmet medical need. I look forward to working closely with the team to advance these programs from early discovery through clinical development and ultimately to patients.”
About Harbour BioMed
Harbour BioMed (stock code: 02142.HK) is a global biopharmaceutical company dedicated to the research and development of innovative drugs in immunology, oncology, and other therapeutic areas. The company rapidly expands its innovative drug pipeline through proprietary research, collaborative development, and diversified international partnerships.
Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both heavy chain-only (HCAb) and conventional dual-heavy and dual-light chain (H2L2) formats. The immune cell engager platform (HBICE®), developed based on the HCAb platform, enables anti-tumor efficacy unattainable by traditional combination therapies. Additionally, the HCAb PLUSTM technology, built on the HCAb platform, provides comprehensive new molecular solutions for innovative multispecific drug development across various disease areas. Furthermore, leveraging the Harbour Mice® platform, Harbour BioMed has launched its first fully human AI HCAb model—a fully human HCAb generation and screening model—driven by its Hu-mAtrIxTM artificial intelligence (AI) platform, accelerating the development of innovative therapies.
Harbour Mice®, HBICE®, HCAb PLUSTM, the single B-cell cloning screening platform, and AI technology together form Harbour BioMed’s next-generation innovative therapeutic antibody research and development engine. For more information, please visit: www.harbourbiomed.com.